



Cloud-based intelligent platform to accelerate
personalized drug discovery

Efficient. Flexible. Patient-centric.



EIT Health is supported by the EIT,
a body of the European Union



Mayfield





18 years

+ 400 failed trials

1 treatment

Heterogenous diseases are hard to crack



Poor biological
knowledge



Failure of
one-drug-fits-all



Stratification

Personalized clinical trials have massive challenges



Invasive



Difficult to access

\$0.7B baseline

\$5.5B

Significantly more expensive

90% of patients leave clinical trials



How many promising drugs will be abandoned or their evaluation seriously delayed?"


- President, Global Alzheimer's Platform Foundation

NATION & WORLD

Posted June 5 | Updated June 5

Pfizer had clues its blockbuster drug could prevent Alzheimer's. Why didn't it tell the world?

iLoF Platform: Building a cloud-based library of personalised biomarkers and biological profiles



Minimally-invasive
Fits clinical workflow



Scalable
Distributed results




Fast
3 minutes




Low cost
Using Light and AI

Overcoming limitations of traditional 'omics to create patient molecular phenotypes



Integrating large volumes of optical and clinical data to create rapid phenotyping and prediction tools



Our roadmap

 Drug Discovery & Development

 Healthcare Market

 Dependent on breakthrough


Patient recruitment
for clinical trials


Drug-efficacy
tracking


Personalized
risk score


Companion
diagnostic



Case Study 1: Commercial collaboration with a biotech company developing an Alzheimer's therapeutic



Biotech X

Client Biotech developing a drug for Alzheimer's Disease

Target Peptide Y expressed in the brain

Goal Demonstrate iLoF's sensitivity to detect and quantify peptide of interest in blood samples

Future applications

- 1) Patient screening for clinical trials
- 2) Companion diagnostic

Case Study 2: Prognosis in infections diseases with a healthcare provider



Hospital X

Client Large public Hospital

Problem Difficulty managing influx of COVID-19 patients, and optimizing resources

Goal Demonstrate iLoF's ability to stratify COVID-19 patients based on likelihood of ICU admission

Future applications

- 1) Managing ICU occupancy
- 2) Personalizing treatment

Future vision



Using AI to accelerate
personalized treatments for
complex diseases

MULTIPLE SCLEROSIS



PARKINSON




COVID-19



BRAIN TUMORS



Health insights platform driven by iLoF tech platform and enabled by a cloud-based library of biological profiles



Current traction



>1000

Biological profiles stored



Maastricht
University



Banner
Alzheimer's
Institute

12

Academic and Research partners



2

Big Pharma engagements



+ 6M

Seed Funding (€)



3

Commercial studies



TC
TechCrunch

FT
FINANCIAL
TIMES

30
UNDER
30
Forbes

>10

Awards

"A good life is a collection of
happy memories"

-Doris Whaley



Cloud-based intelligent
platform to transform
drug discovery

Luis Valente, Co-Founder & CEO

lvalente@ilof.tech

